Royalty Report: Drugs, Pharmaceuticals, Disease – Collection: 4095


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Disease
  • Therapeutic
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4095

License Grant
On May 20, 2008, the Company entered into an option Agreement with a undisclosed for patent rights to technology that may be used for a second generation product candidate in the field of development and commercialization of oral testosterone, or T, replacement therapy. That option Agreement was converted into an exclusive License Agreement on March 3, 2009.
Field of Use
The rights granted apply to the medical industry relating in the field of development and commercialization of oral testosterone, or T, replacement therapy.

IPSCIO Record ID: 63694

License Grant
As part of the termination, the Company reacquired the rights to the intellectual property.  All obligations under the prior license agreement have been completed except for a perpetual royalty on net sales for LPCN 1021.
License Property
LPCN 1021 An Oral Product Candidate for Testosterone Replacement Therapy

LPCN 1021 is an oral formulation of the chemical testosterone undecanoate (TU), an eleven carbon side chain attached to testosterone. TU is an ester prodrug of testosterone. An ester is chemically formed by bonding an acid and an alcohol. Upon the cleavage, or breaking, of the ester bond, testosterone is formed. TU has been approved for use outside the United States for many years for delivery via intra-muscular injection and in oral dosage form and TU has received regulatory approval in the United States for delivery via intra-muscular injection. We are using our Lip’ral technology to facilitate steady gastrointestinal solubilization and absorption of TU for twice daily oral dosing of TU.

Field of Use
This agreement pertains to the drug industry relating to testosterone.

IPSCIO Record ID: 28250

License Grant
In May 2015, the Licensee acquired from the Licensor the approved new drug application for the previously-Licensed testerone gel product. Pursuant to the terms of the purchase Agreement, upon commercialization, the Licensee will pay a royalty as a result of commercial sale of the product.
License Property
The Licensor's Testosterone gel is an androgen indicated for replacement therapy in males for conditions associated with deficiency or absence of endogenous testosterone including primary hypogonadism and hypogonadotropic hypogonadism.
Field of Use
The Licensee acquired a testosterone gel product for commercialization.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.